Israel's PolyPid just raised $22 million from new investor Shavit Capital and others in a bid to put its lead surgical drug reservoir candidate into Phase III. The candidate releases the antibiotic doxycycline hyclate over four weeks, and is intended for patients suffering from severe open tibia fractures who are at high risk of infection. More